IL33 and asthma: Although no clinical trials of IL-33 inhibitors in CSU are ongoing, phase 2 studies are currently investigating the use of anti-IL-33 antibodies in other Th2-mediated inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD), which share some immunopathological features with CSU.